Business Context and Reporting Period
This Form 8-K was filed by Palisade Bio, Inc. (formerly Seneca Biopharma, Inc.) on May 20, 2021, reporting events occurring between April 27, 2021, and May 25, 2021. The filing details the completion of a merger with Leading Biosciences, Inc. (LBS) and associated financing activities, including the issuance of unregistered equity securities and warrants.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or operating margins. Instead, it focuses on capital structure changes resulting from the merger and financing:
- Pre-Merger Financing: Aggregate purchase price of $20.0 million from Altium Growth Fund, LP.
- Debt Obligations: Unsecured promissory notes with an aggregate principal amount of $0.6 million and a 10% annual interest rate.
- Equity Issuances:
- 118,833 shares of Common Stock issued to Ecoban Securities, LLC as a success fee.
- 3,670,001 shares of Common Stock disbursed from escrow to the Investor (Altium Growth Fund, LP) following a price reset.
Material Changes and Transactions
The primary material changes involve the restructuring of equity and debt instruments following the merger:
- Merger Completion: The merger with LBS was completed on April 27, 2021, with LBS surviving as a wholly-owned subsidiary.
- Warrant Issuances:
- Ecoban Warrant: Issued May 25, 2021, for 18,353 shares at an exercise price of $17.72 per share.
- Investor Equity Warrant: Issued May 20, 2021, for 4,995,893 shares at an exercise price of $5.53 per share. This warrant is immediately exercisable with a five-year term.
- Noteholder Warrants: Old warrants (70,000 shares at $0.73) were converted and subsequently canceled. New warrants for 8,000 shares at $6.00 per share were issued to Noteholders.
- Debt Amendment: The maturity date of the $0.6 million promissory notes was extended to November 15, 2021.
Outlook, Risks, and Contingencies
The filing outlines specific contingencies related to the Pre-Merger Financing agreement:
- Price Reset Mechanism: 3,977,676 shares were initially placed in escrow. If the Company's stock price falls below the purchase price during specific 10-day trading periods (ending on the 16th, 45th, 90th, and 135th days post-merger), additional shares are issued to the Investor to make up the difference.
- Escrow Disbursement: As of the first reset period, 3,670,001 shares were disbursed to the Investor, subject to escrow agent instructions.
- Regulatory Status: All securities issued in these transactions were unregistered, relying on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D exemptions for accredited investors.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance of the 3,670,001 escrow shares and the 118,833 success fee shares.
- Confirm the dilution impact of the 4,995,893 shares underlying the Investor Equity Warrant at the $5.53 exercise price.
- Review the terms of the remaining escrow shares (approximately 307,675) and the conditions for future price resets on days 45, 90, and 135.
- Assess the liquidity implications of the $0.6 million debt maturing on November 15, 2021.
- Check for any subsequent filings regarding the resale registration of the unregistered warrants and shares.